BSE filing, NSE: REGAL. Summary written from the filing by ALFA Finder's alert engine.
Regal Entertainment & Consultants Ltd: key numbers
- Share price
- ₹17.89
- Market cap
- ₹15.94 Cr
- Revenue (annual)
- ₹0.90 Cr
- Net profit (annual)
- ₹0.05 Cr
- P/E (TTM)
- 311.9×Sector 21.1×
- Promoter holding
- 27.00%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Regal Entertainment & Consultants Ltd
All →Regal Entertainment & Consultants Management Change
Regal Entertainment and Consultants appointed Mr. Satbir Singh as Executive Director effective 16 November 2026 for 16 months. He brings over 35 years of experience from IFCI Ltd.
- Execution
- 16 months
Regal Entertainment & Consultants Q2 FY27 Results: Net Loss of ₹0.1 Cr
Regal Entertainment & Consultants Ltd reported revenue from operations of ₹0.2 Cr (-33.3% YoY) and a net loss of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.1 Cr
Regal Entertainment & Consultants Board Meeting Date
Regal Entertainment & Consultants intimated that its 3rd Board Meeting for FY 2026-27 is scheduled for 2 November 2026 to consider unaudited Q2/H1 financials. The trading window remains closed until 4 November 2026.
Regal Entertainment & Consultants Other Announcement
Regal Entertainment & Consultants submitted the quarterly investor complaints statement for the period ended 30th September 2026, complying with SEBI LODR Regulation 13(3) requirements.
Regal Entertainment & Consultants Capital Structure Change
Northern Lights Ventures Private Limited acquired 2,51,103 shares of Regal Entertainment & Consultants Limited via open market transactions. This filing discloses the resulting stake change.
Regal Entertainment & Consultants Other Announcement
The company submitted details of its Compliance Officer and RTA as per SEBI (LODR) Regulations, 2015 for the quarter ended September 30, 2026.
Other regulatory approval announcements
All →Senores Pharmaceuticals Regulatory Approval
Senores Pharmaceuticals disclosed that its subsidiary Ratnatris Pharmaceuticals' Mehsana facility received PIC/S GMP certification from Ukraine's SMDC. The certificate, issued 16 November 2026, opens a wider pathway to regulatory approvals.
Xtglobal Infotech Regulatory Approval
XTGlobal received RBI approval for a ₹0.10 Crore (EUR 10,000) equity investment in its Irish subsidiary. The initial capital supports its European expansion plans.
- Value
- ₹0.10 Cr
Biocon Regulatory Approval
Biocon received U.S. FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta, its fifth oncology biosimilar approved in the US. A global settlement with Genentech sets the earliest US launch in Q3 2028.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Binimetinib tablets, securing 180 days of generic drug exclusivity for the product.
United Breweries Regulatory Approval
United Breweries received BIADA's final order restoring its 42-acre Patna land allotment under the Amnesty Policy 2025, subject to conditions. Commercial production milestones must be met within 24 months.
Bhageria Industries Regulatory Approval
Bhageria Industries received EDQM attestation of GMP inspection for its Vapi facility, confirming EU GMP compliance for Dexamethasone under CEP No. 2024-138. No monetary value is disclosed.